We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Taysha Gene Therapies Inc (TSHA) USD0.00001

Sell:$2.47 Buy:$2.48 Change: $0.1 (4.20%)
NASDAQ:0.81%
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
Sell:$2.47
Buy:$2.48
Change: $0.1 (4.20%)
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
Sell:$2.47
Buy:$2.48
Change: $0.1 (4.20%)
Market closed |  Prices as at close on 6 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

Contact details

Address:
3000 Pegasus Park Drive, Suite 1430
DALLAS
75247
United States
Telephone:
+1 (214) 6120000
Website:
https://tayshagtx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TSHA
ISIN:
US8776191061
Market cap:
$508.26 million
Shares in issue:
204.94 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sean Nolan
    Chairman of the Board, Chief Executive Officer
  • Sukumar Nagendran
    President, Head of Research and Development, Director
  • Kamran Alam
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.